Cargando…

Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)

PURPOSE OF REVIEW: Over the last years, we have learned that the metabolic phenotype of immune cells is closely connected to the cell’s effector function. Understanding these changes will allow us to better understand allergic disease pathology and improve allergy treatment by modulating immune meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Y.-J., Goretzki, A., Rainer, H., Zimmermann, J., Schülke, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832094/
https://www.ncbi.nlm.nih.gov/pubmed/36520269
http://dx.doi.org/10.1007/s11882-022-01058-7
_version_ 1784867989209743360
author Lin, Y.-J.
Goretzki, A.
Rainer, H.
Zimmermann, J.
Schülke, Stefan
author_facet Lin, Y.-J.
Goretzki, A.
Rainer, H.
Zimmermann, J.
Schülke, Stefan
author_sort Lin, Y.-J.
collection PubMed
description PURPOSE OF REVIEW: Over the last years, we have learned that the metabolic phenotype of immune cells is closely connected to the cell’s effector function. Understanding these changes will allow us to better understand allergic disease pathology and improve allergy treatment by modulating immune metabolic pathways. As part two of a two-article series, this review reports on the recent studies investigating the metabolism of the cell types involved in allergies and discusses the initial application of these discoveries in allergy treatment. RECENT FINDINGS: The cell types involved in allergic reactions display pronounced and highly specific metabolic changes (here discussed for epithelial cells, APCs, ILC2s, mast cells, eosinophils, and Th2 cells). Currently, the first drugs targeting metabolic pathways are tested for their potential to improve allergy treatment. SUMMARY: Immune-metabolic changes observed in allergy so far are complex and depend on the investigated disease and cell type. However, our increased understanding of the underlying principles has pointed to several promising target molecules that are now being investigated to improve allergy treatment.
format Online
Article
Text
id pubmed-9832094
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-98320942023-01-12 Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2) Lin, Y.-J. Goretzki, A. Rainer, H. Zimmermann, J. Schülke, Stefan Curr Allergy Asthma Rep Allergens (RK Bush and S Vieths, Section Editors) PURPOSE OF REVIEW: Over the last years, we have learned that the metabolic phenotype of immune cells is closely connected to the cell’s effector function. Understanding these changes will allow us to better understand allergic disease pathology and improve allergy treatment by modulating immune metabolic pathways. As part two of a two-article series, this review reports on the recent studies investigating the metabolism of the cell types involved in allergies and discusses the initial application of these discoveries in allergy treatment. RECENT FINDINGS: The cell types involved in allergic reactions display pronounced and highly specific metabolic changes (here discussed for epithelial cells, APCs, ILC2s, mast cells, eosinophils, and Th2 cells). Currently, the first drugs targeting metabolic pathways are tested for their potential to improve allergy treatment. SUMMARY: Immune-metabolic changes observed in allergy so far are complex and depend on the investigated disease and cell type. However, our increased understanding of the underlying principles has pointed to several promising target molecules that are now being investigated to improve allergy treatment. Springer US 2022-12-15 2023 /pmc/articles/PMC9832094/ /pubmed/36520269 http://dx.doi.org/10.1007/s11882-022-01058-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Allergens (RK Bush and S Vieths, Section Editors)
Lin, Y.-J.
Goretzki, A.
Rainer, H.
Zimmermann, J.
Schülke, Stefan
Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)
title Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)
title_full Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)
title_fullStr Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)
title_full_unstemmed Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)
title_short Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)
title_sort immune metabolism in th2 responses: new opportunities to improve allergy treatment — cell type-specific findings (part 2)
topic Allergens (RK Bush and S Vieths, Section Editors)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832094/
https://www.ncbi.nlm.nih.gov/pubmed/36520269
http://dx.doi.org/10.1007/s11882-022-01058-7
work_keys_str_mv AT linyj immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2
AT goretzkia immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2
AT rainerh immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2
AT zimmermannj immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2
AT schulkestefan immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2